Production and process controls, organization and personnel were the top problems found, while packaging and labeling citations increased in 2017 and 2018.
Naheed Sayeed
Advertisement
Articles by Naheed Sayeed
Advertisement
Latest Updated Articles
- Lessons from FDA 483s and cGMP Inspection Data
Published: December 15th 2019 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership
2
Executive Summary: Mastering Nitrosamines Analysis With Streamlined LC-MS/MS Solutions
3
AstraZeneca Lupus Treatment Support in EU Opens Door for Self-Administration Options
4
Why Radiopharmaceuticals Are Ideal for Treating Cancer
5
